Efficacy and Safety of Oral Antiviral Therapy for Idiopathic Trigeminal Neuralgia

Starting soon · Not applicable

Conditions studied: Idiopathic Trigeminal Neuralgia

In brief

This is a multicenter, prospective, randomized, controlled trial. A total of 165 patients with idiopathic trigeminal neuralgia will be enrolled and randomly divided into three groups at a 1:1:1 ratio. The aim is to compare the efficacy and safety of conventional carbamazepine monotherapy, carbamazepine combined with oral antiviral therapy, and carbamazepine combined with anti-inflammatory therapy in pain relief, quality of life improvement and adverse event profiles.

Key facts

Study ID

NCT07673549

Run by

Beijing Tiantan Hospital

People needed

165

Starts

2026-08-31

Expected to finish

2027-12-31

Last updated by the study team

2026-06-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosed with idiopathic trigeminal neuralgia according to standard clinical criteria.
• No secondary etiology confirmed by cranial imaging.
• No severe systemic disease or immune system disease.
• Voluntary participation and signed informed consent.

You may not qualify if…

• Secondary trigeminal neuralgia of any cause.
• Active herpes zoster infection recently.
• Severe hepatic or renal insufficiency or contraindications to study drugs.
• Unable to complete questionnaire evaluation independently.
• Pregnancy or lactation state. -

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.